A multicentre, double-blind, randomized controlled trial of inhaled amikacin versus placebo in critically ill patients with ventilator-associated tracheobronchitis (AMIVAT)

Conditions

Patients with ventilator-associated tracheobronchitis

Brief summary

Incidence of transition from VAT to VAP at Day 28

Detailed description

Incidence of transition from VAT to VAP at Day 7, Overall incidence of a first VAP episode (all pathogens) at Day 28, Overall incidence of a first VAP episode due to MDRB at Day 28, Time to resolution of clinical signs of VAT, Persistence of the pathogens responsible for VAT on ETA at Day 7, Total duration of MV, Number of ventilator-free days at Day 28, Number of defined daily doses of systemic antibiotics (i.e., intravenous and/or enteral administration) at Day 28, Incidence of ICU-acquired intestinal colonization with MDRB at Day 28, Overall incidence of ICU-acquired infection due to MDRB at Day 28, ICU and hospital LOS, All-cause Day-28 and Day-90 mortality rates, HRQoL in survivors at Day 90, Occurrence of respiratory adverse events related to amikacin nebulization (safety analysis), Incidence of AKI at Day 28 (safety analysis), Pharmacokinetics of inhaled amikacin (pre-planned subsample).

Related papers

No related papers found yet.

Interventions

DRUGCHLORURE DE SODIUM 0

DRUG9 % COOPER

DRUGsolution pour perfusion

DRUGAMIKACINE VIATRIS 1 g

DRUGpoudre pour solution injectable en flacon

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of transition from VAT to VAP at Day 28	—

Secondary

Measure	Time frame
Incidence of transition from VAT to VAP at Day 7, Overall incidence of a first VAP episode (all pathogens) at Day 28, Overall incidence of a first VAP episode due to MDRB at Day 28, Time to resolution of clinical signs of VAT, Persistence of the pathogens responsible for VAT on ETA at Day 7, Total duration of MV, Number of ventilator-free days at Day 28, Number of defined daily doses of systemic antibiotics (i.e., intravenous and/or enteral administration) at Day 28, Incidence of ICU-acquired intestinal colonization with MDRB at Day 28, Overall incidence of ICU-acquired infection due to MDRB at Day 28, ICU and hospital LOS, All-cause Day-28 and Day-90 mortality rates, HRQoL in survivors at Day 90, Occurrence of respiratory adverse events related to amikacin nebulization (safety analysis), Incidence of AKI at Day 28 (safety analysis), Pharmacokinetics of inhaled amikacin (pre-planned subsample).	—

Measure

Time frame

Incidence of transition from VAT to VAP at Day 7, Overall incidence of a first VAP episode (all pathogens) at Day 28, Overall incidence of a first VAP episode due to MDRB at Day 28, Time to resolution of clinical signs of VAT, Persistence of the pathogens responsible for VAT on ETA at Day 7, Total duration of MV, Number of ventilator-free days at Day 28, Number of defined daily doses of systemic antibiotics (i.e., intravenous and/or enteral administration) at Day 28, Incidence of ICU-acquired intestinal colonization with MDRB at Day 28, Overall incidence of ICU-acquired infection due to MDRB at Day 28, ICU and hospital LOS, All-cause Day-28 and Day-90 mortality rates, HRQoL in survivors at Day 90, Occurrence of respiratory adverse events related to amikacin nebulization (safety analysis), Incidence of AKI at Day 28 (safety analysis), Pharmacokinetics of inhaled amikacin (pre-planned subsample).

—

Countries

France

Outcome results

None listed